India's CRDMO Sector Poised for Growth: A Global Leadership Opportunity

India's Contract Research Development and Manufacturing Organisation (CRDMO) sector is poised for substantial growth, potentially reaching USD 22-25 billion by 2035. Currently holding a small market share globally, India is positioned to become a leader in the sector, driven by supply chain de-risking, advanced modality demand, and increased R&D investments.

India’s Contract Research Development and Manufacturing Organisation (CRDMO) sector stands at a pivotal juncture, with projections indicating its growth to USD 22-25 billion by 2035, according to a report by Boston Consulting Group and Innovative Pharmaceutical Services Organization.

Driving this growth are several factors, including efforts to de-risk supply chains, making India an attractive outsourcing choice. Inflationary pressures and policies like the Inflation Reduction Act have accelerated offshoring, while demand for advanced modalities such as ADCs, gene therapy, and RNA therapeutics boosts specialized CRDMO services.

However, the sector faces critical challenges, including a need for talent expansion, faster regulatory processes, and a stronger supplier base. Addressing these, along with infrastructural investments, will be essential for India to realize its potential as a global CRDMO leader, noted Vikash Agarwalla, Managing Director at BCG.